VIDEO: Combining dasatinib with prednisone, blinatumomab appears safe in ALL subtype
Combining the tyrosine kinase inhibitor dasatinib with prednisone and blinatumomab seemed safe in older patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, researchers reported.
Based on phase 2 study results presented at the ASH Annual Meeting and Exposition, Anjali Advani, MD, director of the inpatient leukemia program at Cleveland Clinic’s Taussig Cancer Institute, told Healio in a video interview that there did not seem to be increased toxicity and the early results “look encouraging.”
“Right now, we have about 1.7 years of median follow-up, so definitely longer follow-up is needed,” Advani said. “But from the trial, at least the projected 3-year and disease-free survivals are excellent — around about 85% — which, if that holds up with longer follow-up, would be very encouraging. So, we’re pretty excited about that.”
Collapse
Advani A, et al. Abstract 3397. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.